Galactooligosaccharide (GOS) Supplementation and Calcium Absorption in Girls (Friesland)
This study has been completed.
Sponsor:
Purdue University
Collaborator:
Friesland Foods
Information provided by:
Purdue University
ClinicalTrials.gov Identifier:
NCT01263847
First received: March 29, 2010
Last updated: January 12, 2011
Last verified: January 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine the effects of galactooligosaccharide (GOS) supplementation on calcium absorption and and gut microbe profiles.
| Condition | Intervention | Phase |
|---|---|---|
|
Osteoporosis |
Dietary Supplement: Galactooligosaccharide |
Phase 0 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Crossover Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Prevention |
| Official Title: | The Effect of Galactooligosaccharide (GOS) Supplementation on Calcium Absorption and Retention in Female Adolescent Girls |
Resource links provided by NLM:
Further study details as provided by Purdue University:
Primary Outcome Measures:
- Calcium Absorption [ Time Frame: baseline and 48 h urine and blood ] [ Designated as safety issue: No ]Calcium absorption will be measured using dual isotope methods. Calcium-44(Ca-44) as calcium chloride will be administered in a yogurt drink provided at breakfast along with a roll, butter, jam and juice. A second isotope, Calcium-43 (Ca-43) as calcium chloride will be administered intravenously, one hour after consumption of breakfast. Urine and blood samples will be collected over a period of 48 hours and levels of Ca-44 and Ca-43 will be measured in urine and blood. Levels of Ca-44 and Ca-43 will be expressed as a ratio (Ca-44/Ca-43).
Secondary Outcome Measures:
- Change in fecal microbiota [ Time Frame: after 3 weeks of product consumption ] [ Designated as safety issue: No ]
| Enrollment: | 31 |
| Study Start Date: | June 2009 |
| Study Completion Date: | July 2010 |
| Primary Completion Date: | July 2010 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Placebo Comparator: No Galactooligosaccharide
0 g galactooligosaccharide added to calcium-containing yogurt beverage
|
Dietary Supplement: Galactooligosaccharide
Zero, 5 or 10 g/day of galactooligosaccharide will be administered in two yogurt drinks containing about 300 mg total calcium each per day for three weeks. During a clinical visit following three weeks of consumption, zero, 2.5 or 5 g of galactooligosaccharide will be administered in the same yogurt with the addition of 15 mg Ca-44 (calcium chloride). Participants will be given one of the above yogurts at breakfast in addition to intravenously receiving 3.5 mg Ca-43 (calcium chloride) in 4 ml saline one hour after breakfast consumption.
Other Name: Friesland
|
|
Active Comparator: 5 g Galactooligosaccharide
5 g galactooligosaccharide provided in two calcium-containing yogurt beverage (2.5 g in each drink) per day
|
Dietary Supplement: Galactooligosaccharide
Zero, 5 or 10 g/day of galactooligosaccharide will be administered in two yogurt drinks containing about 300 mg total calcium each per day for three weeks. During a clinical visit following three weeks of consumption, zero, 2.5 or 5 g of galactooligosaccharide will be administered in the same yogurt with the addition of 15 mg Ca-44 (calcium chloride). Participants will be given one of the above yogurts at breakfast in addition to intravenously receiving 3.5 mg Ca-43 (calcium chloride) in 4 ml saline one hour after breakfast consumption.
Other Name: Friesland
|
|
Active Comparator: 10 g Galactooligosaccharide
10 g galactooligosaccharide added to two calcium-containing yogurt beverage (5 g in each drink) per day
|
Dietary Supplement: Galactooligosaccharide
Zero, 5 or 10 g/day of galactooligosaccharide will be administered in two yogurt drinks containing about 300 mg total calcium each per day for three weeks. During a clinical visit following three weeks of consumption, zero, 2.5 or 5 g of galactooligosaccharide will be administered in the same yogurt with the addition of 15 mg Ca-44 (calcium chloride). Participants will be given one of the above yogurts at breakfast in addition to intravenously receiving 3.5 mg Ca-43 (calcium chloride) in 4 ml saline one hour after breakfast consumption.
Other Name: Friesland
|
Detailed Description:
Galactooligosaccharides (GOS) have been shown to have positive effects on calcium absorption in animals and postmenopausal women. This study aims to see whether the addition of fiber in the form of GOS to a calcium-containing yogurt drink will increase calcium absorption compared to placebo in a group of girls near menarche. Secondary outcomes are to assess physical fitness and determine the relationship between physical fitness and calcium absorption in adolescent girls as well as assess changes in gut microbiota. During this three phase, randomized, controlled crossover study, participants will consume yogurt drinks supplemented with 0, 2.5 or 5 grams of GOS twice daily for three weeks. Following each three week period, participants will complete a weekend clinical visit to measure calcium absorption. Height, weight, bone density and geometry, calcium absorption, gut microbiota and physical fitness will be measured. Effects of this GOS fiber intervention may help elucidate a mechanism of action for improving bone health with fiber supplementation.
Eligibility| Ages Eligible for Study: | 10 Years to 12 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Female between ages of 10 and 12
- Calcium intake of 900-1300 mg/d
Exclusion Criteria:
- Take medication that influences calcium metabolism
- Any disorder of calcium or bone homeostasis
- BMI>90th percentile for age
- Smoking, illegal drug consumption
- Any gastrointestinal disease (crohn's disease, celiac disease, inflammatory bowel disease)
- Any disease affecting kidney function
- Broken bone within last 6 months
- Dislike of yogurt or yogurt drinks
- Regular use of foods containing probiotics or prebiotics
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01263847
Locations
| United States, Indiana | |
| Purdue University | |
| West Lafayette, Indiana, United States, 47907 | |
Sponsors and Collaborators
Purdue University
Friesland Foods
Investigators
| Principal Investigator: | Connie M Weaver, PhD | Purdue University |
More Information
No publications provided
| Responsible Party: | Connie M Weaver, PhD, Purdue University |
| ClinicalTrials.gov Identifier: | NCT01263847 History of Changes |
| Other Study ID Numbers: | Friesland |
| Study First Received: | March 29, 2010 |
| Last Updated: | January 12, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by Purdue University:
|
Dietary Supplement: Galactooligosaccharide |
Additional relevant MeSH terms:
|
Osteoporosis Bone Diseases, Metabolic Bone Diseases Musculoskeletal Diseases |
Calcium, Dietary Bone Density Conservation Agents Physiological Effects of Drugs Pharmacologic Actions |
ClinicalTrials.gov processed this record on June 18, 2013